Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
    (Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
    (Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
    (Date:12/19/2014)... (PRWEB) December 18, 2014 Today, ... locate its pilot production facility and future company ... and produce innovative new materials that safely and ... not only because of its historic, strong support ... efforts to attract leading edge, technology-based companies such ...
    Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
    ... May 19, 2011 Ardea Biosciences, Inc. (Nasdaq: ... completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY ... an Oral Abstract Session at the 2011 American Society ... on Sunday, June 5, 2011. Presentation ...
    ... 19, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... $5 million milestone payment from GlaxoSmithKline (GSK) related to ... ISIS-TTRRx.  ISIS-TTRRx is designed to treat transthyretin amyloidosis, a ... of peripheral nerve and/or heart tissues . ISIS-TTRRx ...
    ... YORK, May 19, 2011 Reportlinker.com ... report is available in its catalogue: ... (MEMs) Devices Industry ... report analyzes the worldwide markets for ...
    Cached Biology Technology:Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting 2Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 2Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 3Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline 4Global Micro-Electromechanical Systems (MEMs) Devices Industry 2Global Micro-Electromechanical Systems (MEMs) Devices Industry 3Global Micro-Electromechanical Systems (MEMs) Devices Industry 4Global Micro-Electromechanical Systems (MEMs) Devices Industry 5Global Micro-Electromechanical Systems (MEMs) Devices Industry 6Global Micro-Electromechanical Systems (MEMs) Devices Industry 7Global Micro-Electromechanical Systems (MEMs) Devices Industry 8Global Micro-Electromechanical Systems (MEMs) Devices Industry 9Global Micro-Electromechanical Systems (MEMs) Devices Industry 10Global Micro-Electromechanical Systems (MEMs) Devices Industry 11Global Micro-Electromechanical Systems (MEMs) Devices Industry 12Global Micro-Electromechanical Systems (MEMs) Devices Industry 13Global Micro-Electromechanical Systems (MEMs) Devices Industry 14Global Micro-Electromechanical Systems (MEMs) Devices Industry 15Global Micro-Electromechanical Systems (MEMs) Devices Industry 16Global Micro-Electromechanical Systems (MEMs) Devices Industry 17Global Micro-Electromechanical Systems (MEMs) Devices Industry 18Global Micro-Electromechanical Systems (MEMs) Devices Industry 19Global Micro-Electromechanical Systems (MEMs) Devices Industry 20Global Micro-Electromechanical Systems (MEMs) Devices Industry 21Global Micro-Electromechanical Systems (MEMs) Devices Industry 22Global Micro-Electromechanical Systems (MEMs) Devices Industry 23Global Micro-Electromechanical Systems (MEMs) Devices Industry 24
    (Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
    (Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
    (Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
    Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... species in streams begins to occur at the initial stages ... USGS. The study found that streams are more sensitive to ... of waterways as fragile organisms, and yet that is exactly ... telling us," said USGS Director Marcia McNutt. "Streams are more ...
    ... This release is available in French . ... according to a review lead by Gabriel Shapiro of the ... Mother and Child Hospital. Women are at the highest risk ... a child may trigger a depressive episode in vulnerable women. ...
    ... at the National Institute of Standards and Technology (NIST) ... nanotubes (SWCNTs) may help protect DNA molecules from damage ... process in which a reactive chemical removes electrons from ... cells. More studies are needed to see if the ...
    Cached Biology News:Streams show signs of degradation at earliest stages of urban development 2NIST study suggests carbon nanotubes may protect DNA from oxidation 2
    This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
    ... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
    ... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
    ...
    Biology Products: